Geneva, May 18 -- International Clinical Trials Registry received information related to the study (ChiCTR2600124141) titled 'A prospective, single-center, real-world study of telitacicept for the treatment of hematuria in patients with IgA nephropathy' on May 8.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: The Third Xiangya Hospital, Central South University
Condition:
IgA Nephropathy
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-05-10
Target Sample Size: Telitacicept treatment group:36;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=318520
Published by HT Digital Content Services with permission from Health Daily ...